Tazobactam API Manufacturers | Suppliers | Exporters

01

HRV Global Life Sciences

India

PharmaVenue

Not Confirmed

HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Contact Supplier

India

Virtual Booth

Digital Content

Tazobactam Sodium

About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Global effectively promote projects and products. HRV Global represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Global has offices in the US, Switzerland, Dubai, Lithuania & Turkey.

02

CSPC Pharmaceutical Group

China

PharmaVenue

Not Confirmed

03

Hengdian Group

China

PharmaVenue

Not Confirmed

04

Qilu Pharmaceutical

China

PharmaVenue

Not Confirmed

05

Rajasthan Antibiotics

India

PharmaVenue

Not Confirmed

06

Vaishali Pharma Ltd

India

PharmaVenue

Not Confirmed

07

Yuhan Corporation

South Korea

PharmaVenue

Not Confirmed

Yuhan Corporation

South Korea

PharmaVenue

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

South Korea

Virtual Booth

Digital Content

Tazobactam

About the Company : After returning from the USA in 1925, Dr. Ilhan New witnessed the hardship in his country under Japanese imperialism. He founded the Yuhan corporation in 1926 with the belief that ...

After returning from the USA in 1925, Dr. Ilhan New witnessed the hardship in his country under Japanese imperialism. He founded the Yuhan corporation in 1926 with the belief that only healthy people could reclaim their sovereignty and he sought to solve widespread public health problems. Over 80 years, the founding creed to make the best medicines and contribute to public health has been succeeded by us through our intense research and development activities and successful collaboration with multinational pharmaceutical companies. As a result, Yuhan is one of the most respected companies in Korea for 20 consecutive years, according to the annual Korean Management Association Consulting (KMAC) survey. Yuhan has been playing active role in global citizenship since its foundation in 1926. Even before global citizenship was conceptualized, Dr. New believed that was the duty and responsibility of business to develop itself for the prosperity of all society, and his own personal commitment to this was the donation of all of his personal property throughout his life up until his death. Yuhan is continuously making its social contribution by establishing a system where part of the company’s profits is returned to society. This endeavor has been domestically and internationally recognized through various organizations and publications. Yuhan has always emphasized research and development as its top corporate priority. The company approaches R&D through innovative, nimble and translational methodologies. This three-fold dynamic allows Yuhan to continue its over-arching commitment to enhancing quality of life. True to the company’s founding mission, Yuhan focuses its R&D efforts on developing the kinds of products people need most. By developing therapies for treating inflammatory, autoimmune, oncologic and metabolic diseases, Yuhan has significantly advanced the science and understanding of these prevalent disease processes. This rich body of knowledge and wealth of experience positions Yuhan on the cutting edge for developing unique, innovative, finished products and to partnering successfully with other developers. Yuhan has been playing active role in global citizenship since its foundation in 1926. Even before global citizenship was conceptualized, Dr. New believed that was the duty and responsibility of business to develop itself for the prosperity of all society, and his own personal commitment to this was the donation of all of his personal property throughout his life up until his death. Yuhan is continuously making its social contribution by establishing a system where part of the company’s profits is returned to society. This endeavor has been domestically and internationally recognized through various organizations and publications. The R&D Priority Yuhan has always emphasized research and development as its top corporate priority. The company approaches R&D through innovative, nimble and translational methodologies. This three-fold dynamic allows Yuhan to continue its over-arching commitment to enhancing quality of life. True to the company’s founding mission, Yuhan focuses its R&D efforts on developing the kinds of products people need most. By developing therapies for treating inflammatory, autoimmune, oncologic and metabolic diseases, Yuhan has significantly advanced the science and understanding of these prevalent disease processes. This rich body of knowledge and wealth of experience positions Yuhan on the cutting edge for developing unique, innovative, finished products and to partnering successfully with other developers. Yuhan: A Global Best Partner Equipped with state-of-the-art research capabilities and manufacturing facilities compliant with the United States Food and Drug Administration (FDA) current Good Manufacturing Practices (cGMP) regulations, Yuhan is growing into a global pharmaceutical company that offers one-stop custom synthesis services from R&D to commercial production of active pharmaceutical products (APIs) and intermediates. Yuhan has undergone successful audits by many international regulatory agencies such as the FDA, the European Medicines Agency and the European Directorate for the Quality of Medicines (EMEA/EDQM), Australia’s Therapeutic Goods Amdinistration (TGA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). Yuhan has successfully provided high-quality APIs and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets. Yuhan continues to expand its overseas markets by supplying finished products. The process began in 2010 with the out-licensing to China of Yuhan’s Revanex, the world’s first acid pump antagonist (APA). Revanex is now supplied world-wide to India, Southeast Asia, South America and the Middle East, improving the health and quality of life for individuals suffering from peptic ulcers and gastritis-related mucosal injury.

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Tazobactam Manufacturers

A Tazobactam manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tazobactam, including repackagers and relabelers. The FDA regulates Tazobactam manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tazobactam API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Tazobactam manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Tazobactam Suppliers

A Tazobactam supplier is an individual or a company that provides Tazobactam active pharmaceutical ingredient (API) or Tazobactam finished formulations upon request. The Tazobactam suppliers may include Tazobactam API manufacturers, exporters, distributors and traders.

click here to find a list of Tazobactam suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Tazobactam Manufacturers | Traders | Suppliers

We have 7 companies offering Tazobactam

Get in contact with the supplier of your choice:

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Tazobactam

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

28 API Suppliers

16 USDMF

9 JDMF

4 EU WC

2 KDMF

10 NDC API

7 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

129 FDF Dossiers

57 FDA Orange Book

30 Europe

9 South Africa

33 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 40MG BASE/ML;EQ 5MG BASE/ML

INJECTABLE;INJECTION - EQ 4GM BASE/100ML;EQ 500MG BASE/100ML

INJECTABLE;INJECTION - EQ 60MG BASE/ML;EQ 7.5MG BASE/ML

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

1 Faran Shimi Pharmaceutical

1 Pfanstiehl

3 Actylis

1 Pluviaendo

4 Roquette

EXCIPIENTS BY APPLICATIONS

6 Parenteral

2 Fillers, Diluents & Binders

1 Thickeners and Stabilizers

1 API Stability Enhancers

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow

42 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

28 Finished Drug Prices

5 Annual Reports

MARKET PLACE

14 APIs

5 FDF Dossiers

PATENTS & EXCLUSIVITIES

28 US Patents

3 US Exclusivities

REF. STANDARDS & IMPURITIES

1 USP

2 Others

Filters

01

02

03

04

05

06

07

Tazobactam Manufacturers

Tazobactam Suppliers

Tazobactam Manufacturers | Traders | Suppliers

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons